Synthesis and biological evaluation of botulinum neurotoxin a protease inhibitors

Journal of Medicinal Chemistry

Volumn 53, Issue 5, 2010, Pages 2264-2276

  Li, Bing ^a   Pai, Ramdas ^a   Cardinale, Steven C ^a   Butler, Michelle M ^a   Peet, Norton P ^a   Moir, Donald T ^a   Bavari, Sina ^b   Bowlin, Terry L ^a  

^a MICROBIOTIX INC   (United States)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX TOXIN; BOTULINUM TOXIN A; INDOLE BIS AMIDINE; METALLOPROTEINASE; N' (2 (DIMETHYLAMINO)ETHYL) 2 (4 4 N' 2 (DIMETHYLAMINO) ETHYLCARBAMIMIDOYLPHENOXY) PHENYL 1H INDOLE 6 CARBOXIMIDAMIDE; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ASSAY; ENZYME SPECIFICITY; FLUORESCENCE RESONANCE ENERGY TRANSFER; IC 50; LETHAL GENE; LIGHT CHAIN; MOLECULAR MODEL; STRUCTURE ACTIVITY RELATION;

AMIDINES; BENZIMIDAZOLES; BOTULINUM TOXIN TYPE A; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMANS; INDOLES; INHIBITORY CONCENTRATION 50; MAGNETIC RESONANCE SPECTROSCOPY; PROTEASE INHIBITORS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STRUCTURE-ACTIVITY RELATIONSHIP; THIOPHENES;

EID: 77949396534     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm901852f     Document Type: Article

References (32)

1. Burnett, J. C.; Henchal, E. A.; Schmaljohn, A. L.; Bavari, S. The evolving field of biodefence: therapeutic developments and diagnostics. Nat. Rev. Drug Discovery 2005, 4, 281-297.
2. Paddle, B. M. Therapy and prophylaxis of inhaled biological toxins. J. Appl. Toxicol. 2003, 23, 139-170.
3. Clarke, S. C. Bacteria as potential tools in bioterrorism, with an emphasis on bacterial toxins. Br. J. Biomed. Sci. 2005, 62, 40-46.
4. Hicks, R. P.; Hartell, M. G.; Nichols, D. A.; Bhattacharjee, A. K.; van Hamont, J. E.; Skillman, D. R. The medicinal chemistry of botulinum, ricin and anthrax toxins. Curr. Med. Chem. 2005, 12, 667-690.
5. Josko, D. Botulin toxin: a weapon in terrorism. Clin. Lab. Sci. 2004, 17, 30-34.
6. Arnon, S. S.; Schechter, R.; Inglesby, T. V.; Henderson, D. A.; Bartlett, J. G.; Ascher, M. S.; Eitzen, E.; Fine, A. D.; Hauer, J.; Layton, M.; Lillibridge, S.; Osterholm, M. T.; O'Toole, T.; Parker, G.; Perl, T. M.; Russell, P. K.; Swerdlow, D. L.; Tonat, K. Botulinum toxin as a biological weapon: medical and public health management. JAMA, J. Am. Med. Assoc. 2001, 285, 1059-1070.
7. Charles, P. D. Botulinum neurotoxin serotype A: a clinical update on non-cosmetic uses. Am. J. Health-Syst. Pharm. 2004, 61, S11-23.
8. Foran, P. G.; Mohammed, N.; Lisk, G. O.; Nagwaney, S.; Lawrence, G. W.; Johnson, E.; Smith, L.; Aoki, K. R.; Dolly, J. O. Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons. J. Biol. Chem. 2003, 278, 1363-1371.
9. Simpson, L. L. Identification of the major steps in botulinum toxin action. Annu. Rev. Pharmacol. Toxicol. 2004, 44, 167-193.
10. Amersdorfer, P.; Wong, C.; Smith, T.; Chen, S.; Deshpande, S.; Sheridan, R.; Marks, J. D. Genetic and immunological comparison of anti-botulinum type A antibodies from immune and nonimmune human phage libraries. Vaccine 2002, 20, 1640-1648.
11. Nowakowski, A.; Wang, C.; Powers, D. B.; Amersdorfer, P.; Smith, T. J.; Montgomery, V. A.; Sheridan, R.; Blake, R.; Smith, L. A.; Marks, J. D. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 11346-11350.
12. Willis, B.; Eubanks, L. M.; Dickerson, T. J.; Janda, K. D. The strange case of the botulinum neurotoxin: using chemistry and biology to modulate the most deadly poison. Angew. Chem., Int. Ed. 2008, 47, 8360-8379.
13. Schmidt, J. J.; Stafford, R. G. A high-affinity competitive inhibitor of type A botulinum neurotoxin protease activity. FEBS Lett. 2002, 532, 413-416.
14. Solaja, B. A.; Opsenica, D.; Smith, K. S.; Milhous, W. K.; Terzic, N.; Opsenica, I.; Burnett, J. C.; Nuss, J.; Gussio, R.; Bavari, S. Novel 4-aminoquinolines active against chloroquine-resistant and sensitive P. falciparum strains that also inhibit botulinum serotype A. J. Med. Chem. 2008, 51, 4388-4391.
15. Boldt, G. E.; Eubanks, L. M.; Janda, K. D. Identification of a botulinum neurotoxin A protease inhibitor displaying efficacy in a cellular model. Chem. Commun. 2006, 3063-3065.
16. Boldt, G. E.; Kennedy, J. P.; Janda, K. D. Identification of apotent botulinum neurotoxin A protease inhibitor using in situ lead identification chemistry. Org. Lett. 2006, 8, 1729-1732.
17. Moe, S. T.; Thompson, A. B.; Smith, G. M.; Fredenburg, R. A.; Stein, R. L.; Jacobson, A. R. Botulinum neurotoxin serotype A inhibitors: small molecule-mercaptoacetamide analogs. Bioorg. Med. Chem. 2009, 17, 3072-3079.
18. Roxas-Duncan, V.; Enyedy, I.; Montgomery, V. A.; Eccard, V. S.; Carrington, M. A.; Lai, H.; Gul, N.; Yang, D. C. H.; Smith, L. A. Identification and biochemical characterization of small-molecule inhibitors of Clostridium botulinum neurotoxin serptype A. Antimicrob. Agents Chemother. 2009, 53, 3478-3486.
19. Lai, H.; Feng, M.; Roxas-Duncan, V.; Dakshanamurthy, S.; Smith, L. A.; Yang, D. C. H. Quinolinol and peptide inhibitors of zinc protease in botulinum neurotoxin A: effects of zinc ion and peptides on inhibition. Arch. Biochem. Biophys. 2009, 491, 75-84.
20. Pang, Y.-P.; Vummenthala, A.; Mishra, R. K.; Park, J. G.; Wang, S.; Davis, J.; Millard, C. B.; Schmidt, J. J. Potent new smallmolecule inhibitor of botulinum neurotoxin serotype A endopeptidase developed by synthesis-based computer-aided molecular design. PLoS One 2009, 4, No.e7730.
21. Burnett, J. C.; Wang, C.; Nuss, J. E.; Nguyen, T. L.; Hermone, A. R.; Schmidt, J. J.; Gussio, R.; Wipf, P.; Bavari, S. Pharmacophoreguided lead optimization: the rational design of a non-zinc neurotoxin serotype a metalloprotease. Bioorg. Med. Chem. Lett. 2009, 19, 5811-5813.
22. Burnett, J. C.; Ruthel, G.; Stegmann, C. M.; Panchal, R. G.; Nguyen, T. L.; Hermone, A. R.; Stafford, R. G.; Lane, D. J.; Kenny, T. A.; McGrath, C. F.; Wipf, P.; Stahl, A. M.; Schmidt, J. J.; Gussio, R.; Brunger, A. T.; Bavari, S. Inhibition of metalloprotease botulinum serotype A from a pseudo-peptide binding mode to a small molecule that is active in primary neurons. J. Biol. Chem. 2007, 282, 5004-5014.
23. Burnett, J. C.; Opsenica, D.; Sriraghavan, K.; Panchal, R. G.; Ruthel, G.; Hermone, A. R.; Nguyen, T. L.; Kenny, T. A.; Lane, D. J.; McGrath, C. F.; Schmidt, J. J.; Vennerstrom, J. L.; Gussio, R.; Solaja, B. A.; Bavari, S. A refined pharmacophore identifies potent 4-amino-7-chloroquinoline-based inhibitors of the botulinum neurotoxin serotype A metalloprotease. J. Med. Chem. 2007, 50, 2127-2136.
24. Capkova, K.; Hixon, M. S.; Pellett, S.; Barbieri, J. T.; Johnson, E. A.; Janda, K. D. Benzylidene cyclopentenediones: first irreversible inhibitors against botulinum neurotoxin A's zinc endopeptidase. Bioorg. Med. Chem. Lett. 2009, 20, 206-208.
25. Wang, C.; Widom, J.; Petronijevic, F.; Burnett, J. C.; Nuss, J. E.; Bavari, S.; Gussio, R.; Wipf, P. Synthesis and biological evaluation of inhibitors of botulinum neurotoxin metalloprotease. Heterocycles 2009, 79, 487-520.
26. Silvaggi, N. R.; Boldt, G. E.; Hixon, M. S.; Kennedy, J. P.; Tzipori, S.; Janda, K. D.; Allen, K. N. Structures of Clostridium botulinum neurotoxin serotype A light chain complexed with small-molecule inhibitors highlight active-site flexibility. Chem. Biol. 2007, 14, 533-542.
27. Silvaggi, N. R.; Wilson, D.; Tzipori, S.; Allen, K. N. Catalytic features of the botulinum neurotoxin A light chain revealed by high resolution structure of an inhibitory peptide complex. Biochemistry 2008, 47, 5736-5745.
28. Schmidt, J. J.; Stafford, R. G. Fluorigenic substrates for the protease activities of botulinum neurotoxins, serotypes A, B, and F. Appl. Environ. Microbiol. 2003, 69, 297-303.
29. Panchal, R. G.; Hermone, A. R.; Nguyen, T. L.; Wong, T. Y.; Schwarzenbacher, R.; Schmidt, J.; Lane, D.; McGrath, C.; Turk, B. E.; Burnett, J.; Aman, M. J.; Little, S.; Sausville, E. A.; Zaharevitz, D. W.; Cantley, L. C.; Liddington, R. C.; Gussio, R.; Bavari, S. Identification of small molecule inhibitors of anthrax lethal factor. Nat. Struct. Mol. Biol. 2004, 11, 67-72.
30. Butler, M. M.; Cardinale, S. C.; Li, B.; Pai, R.; Ruthel, G.; Nuss, J. E.; Wanner, L. M.; Park, J.-B.; Rich, C.; Basu, A.; Mills, D.; Williams, J. D.; Peet, N. P.; Moir, D.; Bavari, S.; Bowlin, T. L. Unpublished results.
31. Fu, Z.; Chen, S.; Baldwin, M. R.; Boldt, G. E.; Crawford, A.; Janda, K. D.; Barbieri, J. T.; Kim, J. J. Light chain of botulinum neurotoxin serotype A: structural resolution of a catalytic intermediate. Biochemistry 2006, 45, 8903-8911.
32. Kumaran, D.; Rawat, R.; Ludivico, M. L.; Ahmed, S. A.; Swaminathan, S. Structure- and substrate-based inhibitor design for Clostridium botulinum neurotoxin serotype A. J. Biol. Chem. 2008, 255, 18883-18891.